沙美特罗氟替卡松联合噻托溴胺治疗中重度COPD的临床观察

摘要

Objective To observe the effects of salmeterol fluticasone ( Seretide ) combined with tiotropium ( Spiriva ) in the treatment of patients with chronic obstructive pulmonary disease ( COPD ) at moderate and severe stages. Methods 60 COPD patients at moderate and severe stages were randomly divided into two groups. The group A received Seretide inhalation 50 μg/250 μg twice a day and Spiriva inhalation 18 μg once a day. The group B received Seretide inhalation 50 μg/250 μg twice a day only. The total treatment course was 3 months. The blood gas analysis, lung function, and 6-min walking distance were analyzed before and after treatment between the two groups. Results The differences of blood gas analysis, lung function, 6-minute walking distance between the two groups showed statistical significance ( P ＜0. 05 ). Conclusion Salmeterol fluticasone combined with tiotropium has better curative effect in the treatment of COPD patients at moderate and severe stages and it's worth to be promoted and applied in clinical practice.%目的 观察沙美特罗氟替卡松(舒利迭)联合噻托溴胺 (思力华) 治疗中重度COPD患者的临床疗效.方法 将60例中重度COPD稳定期患者随机分成两组,A组:吸入舒利迭(50 μg/250 μg)2次/d,吸入思力华(18 μg)1次/d;B组:吸入舒利迭(50 μg/250μg)2次/d,疗程3个月.以两组治疗前后的血气分析、肺功能、6分钟步行试验为观察指标.结果 A组的血气分析、肺功能、6MWT与B组相比较差异有统计学意义(P<0.05).结论 沙美特罗氟替卡松与噻托溴胺联合治疗中重度COPD患者的效果确切,值得推广.